Lilly and Asahi Kasei Pharma Announce License Agreement for Chronic Pain Drug Candidate

INDIANAPOLIS and TOKYO , Jan. 28, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Asahi Kasei Pharma Corporation today announced a license agreement whereby Lilly will acquire the exclusive rights for AK1780 from Asahi Kasei Pharma . AK1780 is an orally bioavailable P2X7 receptor